GoPro Inc vs Vir Biotechnology Inc. Common Stock — how do they compare? GoPro Inc trades at $1.07 (market cap $243.50M), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Vir Biotechnology Inc. Common Stock is far larger — about 7.4× GoPro Inc's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| GPRO | VIR | |
|---|---|---|
Market Cap | $243.50M | $1.80B |
Volume | 7,074,005 | 1,782,836 |
Sector | Technology | Health |
52-Week High | $2.31 | $11.78 |
52-Week Low | $0.58 | $5.12 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $302.28M | $1.36B |
Signals from Pluang's Aura AI — not financial advice
GoPro trades at $1.16, down 2.52% today, as the stock consolidates after a volatile surge driven by merger news and influencer investment. The company faces fundamental challenges with negative profit margins and cash flow, though valuation ratios appear attractive with P/E of 4.56 and P/S of 0.34. Recent developments include a $285 million merger agreement with Starman Optical and YouTube creator Markiplier taking an 8.5% stake, driving significant price volatility.
The merger with Starman Optical offers strategic repositioning into AI data centers and defense markets, but shareholder lawsuits question the $1.14 per share valuation. While technical indicators show bullish momentum, fundamental weaknesses and competitive pressures from smartphones create significant investment risk. Analyst consensus remains cautious with only 21% buy ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →